Hospital
VHS Harlingen Hospital Company LLC
VHS Harlingen Hospital Company LLC was paid $23.64M by Medicaid between Mar 2019 and Dec 2024, across 137 billing codes. Its largest line is 99284, emergency room visit (serious) — 38% of everything it billed.
33Billing provider infoVHS HARLINGEN HOSPITAL COMPANY LLC
HARLINGEN, TX 78550
HARLINGEN, TX 78550
33aNPI1154618742assigned 07/01/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.64M
24GClaims375,014
24DCodes billed137
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#3 of 109
Median peer was paid$1.15M
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 794 | $25K | |
| 2020 | 8,293 | $382K | |
| 2021 | 78,738 | $4.12M | |
| 2022 | 119,076 | $7.72M | |
| 2023 | 113,633 | $8.51M | |
| 2024incomplete | 54,480 | $2.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 38% | 26,521 | 24,980 | $9.08M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 12,529 | 11,547 | $4.57M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 31,840 | 30,609 | $2.71M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.2% | 24,109 | 19,585 | $982K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.6% | 19,964 | 19,276 | $861K |
| 80053 | Comprehensive metabolic panel | 2.1% | 25,091 | 22,542 | $488K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 8,262 | 7,440 | $486K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 1,111 | 1,053 | $433K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 27,008 | 24,112 | $320K |
| 87430 | 1.3% | 11,661 | 11,378 | $297K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,191 | 3,067 | $231K |
| 59025 | Fetal non-stress test | <1% | 2,344 | 1,690 | $230K |
125 more codes
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,003 | $205K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,299 | $193K |
| G0378 | Hospital observation service, per hour | <1% | 1,398 | $139K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,631 | $139K |
| 81025 | <1% | 7,649 | $133K | |
| 99218 | <1% | 561 | $112K | |
| 87081 | <1% | 9,802 | $106K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,543 | $105K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,642 | $103K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,808 | $98K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 555 | $97K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,783 | $95K |
| 87807 | <1% | 4,928 | $95K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,105 | $86K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 489 | $86K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,904 | $80K |
| 87088 | <1% | 5,934 | $68K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 192 | $66K |
| 81001 | <1% | 10,141 | $60K | |
| 76801 | <1% | 484 | $59K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,247 | $58K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 862 | $55K |
| 84484 | <1% | 4,718 | $51K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,648 | $44K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,425 | $44K |
| 81003 | <1% | 10,110 | $40K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,404 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,302 | $30K |
| 83690 | <1% | 3,054 | $28K | |
| 95816 | <1% | 54 | $28K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,172 | $28K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 415 | $27K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 529 | $27K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,731 | $23K |
| 87040 | <1% | 1,698 | $20K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,814 | $18K |
| 84702 | <1% | 1,056 | $16K | |
| 73610 | <1% | 233 | $16K | |
| 86850 | <1% | 1,061 | $16K | |
| 74270 | <1% | 86 | $15K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,041 | $14K |
| 83605 | <1% | 1,544 | $13K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 70 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,280 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,059 | $11K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 42 | $10K |
| 83880 | <1% | 633 | $10K | |
| 74018 | <1% | 215 | $9K | |
| 87077 | <1% | 1,394 | $8K | |
| 80305 | <1% | 525 | $8K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 56 | $8K |
| 73630 | <1% | 111 | $7K | |
| 87186 | <1% | 1,187 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,093 | $7K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 736 | $6K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 27 | $6K |
| 85730 | <1% | 2,101 | $5K | |
| 85610 | <1% | 2,521 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 16 | $4K |
| 85027 | <1% | 1,637 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,362 | $3K |
| 86901 | <1% | 1,419 | $3K | |
| 86900 | <1% | 1,413 | $3K | |
| 83735 | <1% | 1,035 | $2K | |
| 82550 | <1% | 351 | $2K | |
| 73030 | <1% | 72 | $2K | |
| 73130 | <1% | 25 | $2K | |
| 72082 | <1% | 13 | $2K | |
| 12001 | <1% | 12 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 190 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 776 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 280 | $1K |
| 73560 | <1% | 44 | $1K | |
| 82962 | <1% | 5,753 | $1K | |
| 84703 | <1% | 199 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 587 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 64 | $1K |
| S5010 | 5% dextrose and 0.45% normal saline, 1000 ml | <1% | 88 | $995.48 |
| 90715 | <1% | 42 | $960.20 | |
| 96376 | <1% | 193 | $934.21 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,211 | $857.30 |
| 73140 | <1% | 13 | $786.49 | |
| 73080 | <1% | 12 | $763.62 | |
| 87147 | <1% | 67 | $660.92 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,239 | $637.93 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $635.37 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 30 | $602.82 |
| 87070 | <1% | 292 | $552.52 | |
| 71250 | <1% | 12 | $547.60 | |
| 80061 | Lipid panel | <1% | 117 | $537.58 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 41 | $474.61 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 17 | $429.62 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 196 | $424.95 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 16 | $409.32 |
| 84145 | <1% | 28 | $388.14 | |
| 87486 | <1% | 16 | $351.23 | |
| 87581 | <1% | 16 | $351.23 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 604 | $327.65 |
| 82607 | <1% | 15 | $323.81 | |
| 72100 | <1% | 13 | $319.31 | |
| 82746 | <1% | 15 | $315.65 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 108 | $280.07 |
| 84100 | <1% | 336 | $265.19 | |
| 94664 | <1% | 97 | $226.29 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 28 | $204.05 |
| 84439 | <1% | 12 | $176.30 | |
| 86140 | <1% | 94 | $167.76 | |
| 77080 | <1% | 25 | $159.78 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 178 | $154.40 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 14 | $141.13 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 382 | $139.86 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 76 | $122.28 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 20 | $120.04 |
| 85379 | <1% | 12 | $110.45 | |
| 82150 | <1% | 33 | $71.94 | |
| 82248 | <1% | 12 | $26.13 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,300 | $25.56 |
| C1769 | Guide wire | <1% | 31 | $17.24 |
| 97116 | <1% | 18 | $15.78 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 20 | $1.87 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 12 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 362 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 13 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,527 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRODRIGUEZ, MARCO (CFO)
| Provider | Location | Paid |
|---|---|---|
| VHS Harlingen Hospital Company, LLC | Weslaco, TX | $11.85M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.